Axa S.A. Y M Abs Therapeutics, Inc. Transaction History

Axa S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$29.16 - $51.96 $2.76 Million - $4.92 Million	-94,615 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$37.86 - $54.26 $3.58 Million - $5.13 Million	-94,582 Reduced 49.99%	94,615 $4.68 Million
Q3 2020 Nov 13, 2020	SELL	$35.13 - $43.62 $64,217 - $79,737	-1,828 Reduced 0.96%	189,197 $7.26 Million
Q2 2020 Aug 14, 2020	SELL	$23.66 - $49.53 $1.21 Million - $2.54 Million	-51,255 Reduced 21.16%	191,025 $8.25 Million
Q1 2020 May 15, 2020	BUY	$14.39 - $35.8 $198,135 - $492,930	13,769 Added 6.03%	242,280 $6.32 Million
Q4 2019 Feb 18, 2020	BUY	$23.81 - $33.78 $1.74 Million - $2.47 Million	73,006 Added 46.95%	228,511 $7.14 Million
Q3 2019 Nov 14, 2019	SELL	$21.57 - $31.37 $2,955 - $4,297	-137 Reduced 0.09%	155,505 $4.05 Million
Q2 2019 Aug 13, 2019	BUY	$19.51 - $28.31 $3.04 Million - $4.41 Million	155,642 New	155,642 $3.56 Million

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.